Telix Pharmaceuticals (TLX) Long-Term Deferred Tax (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Long-Term Deferred Tax for 3 consecutive years, with $59.4 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Deferred Tax rose 94.19% year-over-year to $59.4 million; the TTM figure through Dec 2025 stood at $59.4 million (up 94.19% YoY), while the FY2025 annual figure was $59.4 million, up 105.23% from the prior year.
• Long-Term Deferred Tax advanced to $59.4 million in Q4 2025 per TLX's latest filing, from $30.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $59.4 million in Q4 2025 and bottomed at $13.3 million in Q4 2023.
• Historically, Long-Term Deferred Tax has averaged $34.4 million across 3 years, with a median of $30.6 million in 2024.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax surged 129.56% — and 2025, when it surged 94.19%.
• Telix Pharmaceuticals' Long-Term Deferred Tax stood at $13.3 million in 2023, then soared by 129.56% to $30.6 million in 2024, then jumped by 94.19% to $59.4 million in 2025.
• Business Quant data shows TLX's Long-Term Deferred Tax at $59.4 million in Q4 2025, $30.6 million in Q4 2024, and $13.3 million in Q4 2023.